Meet Fernando
54-year-old journalist and father of 3 who recently moved his family across the country to start a new job.
I thought the weight loss was stress from the move. I was shocked when they said it was kidney cancer. I just want to be here to care for my family—I do everything for them.”
MEDICAL HISTORY: Presented with rapid weight loss and lower back pain
INITIAL DIAGNOSIS: Metastatic renal cell carcinoma (RCC) with a clear cell histology; scheduled for laparoscopic nephrectomy
CURRENT STATUS:
- RCC is metastatic and Fernando is treatment naïve
- ECOG performance status: 0
- MSKCC risk: favorable
- Karnofsky performance status (KPS): 90% with minor signs of disease
In COMPARZ, VOTRIENT demonstrated efficacy across a wide range of patients1,2:
85% of patients had a favorable or intermediate MSKCC risk
75% of patients had a 90 or 100 KPS
Patient age ranged from 18 to 88 years
When choosing first-line treatment, what therapy do you consider?
Hypothetical patient case study.
References: 1. VOTRIENT [summary of product characteristics]. Camberley, UK: Novartis Europharm Limited; February 2018. 2. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722-731.
